Enhancing photocatalytic hydrogen peroxide generation by tuning hydrazone linkage density in covalent organic frameworks.

The conversion of solar energy into chemical energy or high-value chemicals has attracted considerable research interest in the context of the global energy crisis. Hydrogen peroxide (HO) is a versatile and powerful oxidizing agent widely used in chemical synthesis and medical disinfection. HO also serves as a clean energy source in fuel cells, generating electricity with zero-carbon emissions.

Nanoscale thickness Octave-spanning coherent supercontinuum light generation.

Coherent broadband light generation has attracted massive attention due to its numerous applications ranging from metrology, sensing, and imaging to communication. In general, spectral broadening is realized via third-order and higher-order nonlinear optical processes (e.g.

TransConv: convolution-infused transformer for protein secondary structure prediction.

Context: Protein secondary structure prediction is essential for understanding protein function and characteristics and can also facilitate drug discovery. Traditional methods for experimentally determining protein structures are both time-consuming and costly. Computational biology offers a viable alternative by predicting protein structures from their sequences.

Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B.

Background: Xalnesiran, a small interfering RNA molecule that targets a conserved region of the hepatitis B virus (HBV) genome and silences multiple HBV transcripts, may have efficacy, with or without an immunomodulator, in patients with chronic HBV infection.

Methods: We conducted a phase 2, multicenter, randomized, controlled, adaptive, open-label platform trial that included the evaluation of 48 weeks of treatment with xalnesiran at a dose of 100 mg (group 1), xalnesiran at a dose of 200 mg (group 2), xalnesiran at a dose of 200 mg plus 150 mg of ruzotolimod (group 3), xalnesiran at a dose of 200 mg plus 180 μg of pegylated interferon alfa-2a (group 4), or a nucleoside or nucleotide analogue (NA) alone (group 5) in participants with chronic HBV infection who had virologic suppression with NA therapy. The primary efficacy end point was hepatitis B surface antigen (HBsAg) loss (HBsAg level, <0.